Kevin Finney

Mr. Finney is president and chief executive officer of Autobahn Therapeutics. He is also the chairman of its board of directors

Mr. Finney has extensive leadership experience in the healthcare industry spanning pharmaceutical, medical device and diagnostic segments, leading companies through the early stages of development to the commercialization of brands. Prior to Autobahn, Mr. Finney was the president and chief operating officer of Abide Therapeutics, where he led the acquisition of Abide by H. Lundbeck A/S in 2019.  Prior to Abide, Mr. Finney was a founder and chief operating officer of Zavante Therapeutics, now known as Nabriva Therapeutics. As a founding member of the management team, he led the initial financing of the company and operations from inception through the sale in 2018. Previously, Mr. Finney was vice president and head of world-wide corporate development at Allergan, Inc., an international specialty pharmaceutical company operating in more than 100 countries worldwide. In this role he led strategic corporate development and was at the center of some of the industry’s largest transactions, including Allergan’s 2015 acquisition by Actavis. During his tenure at Allergan, the company grew from $3 billion in annual revenue to $7 billion through organic and acquired growth, including substantial growth of the neurology franchise with the flagship product BOTOX® (onabotulinumtoxinA).  Prior to Allergan, Mr. Finney held commercial executive management roles at Prometheus Laboratories, Inc. (now Nestle Health Science), Amylin Pharmaceuticals, Inc. (now Bristol-Myers Squibb) and the Parke-Davis division of Warner-Lambert (now Pfizer).  In addition to his role at Autobahn, Mr. Finney serves, or has served, on the boards of Anterios (now Allergan), Taris Biomedical (now J&J) and Eirion Therapeutics. Mr. Finney hold an MBA from the George L. Graziado School of Business, Pepperdine University, and a B.A. in exercise physiology from California State University Long Beach.